Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models

J Med Chem. 2006 Feb 23;49(4):1373-8. doi: 10.1021/jm050901o.

Abstract

Phosphoinositide 3-kinase (PI3K) is an important target for cancer chemotherapy due to the deregulation of its signaling pathway in a wide spectrum of human tumors. Wortmannin and its analogues are potent PI3K inhibitors whose therapeutic use has been impeded by inherent defects such as instability and toxicity. Pegylation of wortmannin and 17-hydroxywortmannin gives rise to conjugates with improved properties, including a higher therapeutic index. Pegylated 17-hydroxywortmannin (8, PWT-458) has been selected for further development.

MeSH terms

  • Androstadienes / chemical synthesis*
  • Androstadienes / chemistry
  • Androstadienes / pharmacology
  • Animals
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Humans
  • Mice
  • Mice, Nude
  • Phosphoinositide-3 Kinase Inhibitors*
  • Polyethylene Glycols / chemical synthesis
  • Polyethylene Glycols / chemistry*
  • Polyethylene Glycols / pharmacology
  • Structure-Activity Relationship
  • Wortmannin
  • Xenograft Model Antitumor Assays

Substances

  • Androstadienes
  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • pegylated 17-hydroxywortmannin
  • 17-hydroxywortmannin
  • Polyethylene Glycols
  • Wortmannin